{"id":751126,"date":"2023-04-25T18:00:03","date_gmt":"2023-04-25T22:00:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/"},"modified":"2023-04-25T18:00:03","modified_gmt":"2023-04-25T22:00:03","slug":"oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/","title":{"rendered":"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.<\/p>\n

The live webcast of the discussion will be available through the investor section of the company\u2019s website at www.oricpharma.com<\/a>. A replay of the webcast will be available for 90 days following the event.<\/p>\n

\n About ORIC Pharmaceuticals, Inc. <\/strong>\n <\/p>\n

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0<\/em>ORIC\u2019s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to\u00a0www.oricpharma.com<\/a>, and follow us on\u00a0Twitter<\/a>\u00a0or\u00a0LinkedIn<\/a>.<\/p>\n

\n Contact:<\/strong>
\n
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com<\/a>
info@oricpharma.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET. The live webcast of the discussion will be available through the investor section of the company\u2019s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0ORIC\u2019s clinical stage product candidates include (1) ORIC-533, an orally bioavailable … <\/p>\n

Continue reading “ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751126","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET. The live webcast of the discussion will be available through the investor section of the company\u2019s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0ORIC\u2019s clinical stage product candidates include (1) ORIC-533, an orally bioavailable … Continue reading "ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T22:00:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference\",\"datePublished\":\"2023-04-25T22:00:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/\"},\"wordCount\":271,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/\",\"name\":\"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=\",\"datePublished\":\"2023-04-25T22:00:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET. The live webcast of the discussion will be available through the investor section of the company\u2019s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0ORIC\u2019s clinical stage product candidates include (1) ORIC-533, an orally bioavailable … Continue reading \"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T22:00:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference","datePublished":"2023-04-25T22:00:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/"},"wordCount":271,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/","name":"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=","datePublished":"2023-04-25T22:00:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTU1NiM1NTMwNzk1IzIwODA4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751126"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751126\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}